About 4 400 reports

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

By Firstword Pharma

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend.Indeed, the chronic heart failure agent is believed to...

516 645 449
Sep 3014

Cancer Drug News 23 FEBRUARY 2015

20 pages • By Espicom Business Intelligence

Industry Trend Analysis - New ACA Initiative To Be Tested To Manage Rising Cancer Costs And Improve Cancer CareIndustry Brief - Eagle Licenses Teva To Commercialise Bendamustine Rapid Infusion In USIndustry Brief - Imbruvica Shows Efficacy/Tolerability In Heavily Treated CLL Patients Following Allo-HCTIndustry Brief - Revlimid...

825 1 114 685
Feb 2015

Medical Marijuana - From Illicit to Legal and Beyond to Pharmaceuticals - Global Markets, Competitors and Opportunities : 2015 - 2020 Analysis and Forecasts

161 pages • By Amadee and Company

The objective of this report is to provide a detailed analysis of the global market for Medical Marijuana. It is also to provide a comprehensive analysis of the leading companies producing these products, as well as the competitive environment they operate in. Marijuana (cannabis) remains a controversial drug in the twenty-first century. However,...

1 560 1 950 1 248
Feb 2015

Therapeutics for ”Silent” Cancers

123 pages • By BCC Research

REPORT HIGHLIGHTSThe global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.This report provides:An overview of the global markets and...

5 320 6 650 4 256
Feb 2015

Cystic Fibrosis Market in Europe 2015-2019

113 pages • By Infiniti Research Limited

About Cystic FibrosisCystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic...

2 400 3 000 1 920
Feb 2015

Radiotherapy: Technologies and Global Markets

130 pages • By BCC Research

REPORT HIGHLIGHTSThe radiation therapy market totaled $5.4 billion in 2013 and $5.8 billion in 2014. The market is expected to reach $8.1 billion in 2019, a compound annual growth rate(CAGR) of 6.7%. This report provides:An overview of the global market for radiotherapy and related technologies and applicationsAnalyses...

5 320 6 650 4 256
Feb 2015

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

82 pages • By MP Advisors

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor’s sub classification. Over...

2 400 3 000 1 920
Feb 2015

Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure

98 pages • By MP Advisors

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology is discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing the life expectancy WW. However, this has not translated into any reduction in the incidence...

2 400 3 000 1 920
Feb 2015

2015 Assessments of Leading Infectious Disease Market Players--Insightful Profiles of Major Suppliers and Emerging Market Entrants

90 pages • By Venture Planning Group

This new report from VPGMarketResearch.com provides strategic assessments of major suppliers of infectious deisease instuments and reagants, as well as emerging market entrants. The report presents strategic assessments of leading market players and emerging suppliers with innovative technologies and products in terms of their sales, product...

1 960 2 450 1 568
Feb 2015

European Sexually-Transmitted Disease Testing Market 2015: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis

318 pages • By Venture Planning Group

Complete report $7,900.  DataPack (test volumes, sales forecasts, supplier shares) $5,100.This new 318-page report from VPGMarketResearch.com provides analysis of the European sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts...

4 080 5 100 3 264
Feb 2015

US Sexually-Transmitted Disease Testing Market 2015: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis

278 pages • By Venture Planning Group

Complete report $4,500.  DataPack (test volumes, sales forecasts, supplier shares) $2,900.This new 278-page report from VPGMarketResearch.com provides analysis of the US sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country,...

2 320 2 900 1 856
Feb 2015

US Respiratory Disease Testing Market 2015: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis

282 pages • By Venture Planning Group

Complete report $4,600.  DataPack (test volumes, sales forecasts, supplier shares) $2, 900.This new 282-page report from VPGMarketResearch.com provides analysis of the US respiratory disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country,...

2 320 2 900 1 856
Feb 2015

2015 Opportunities in the US Diagnostics Market

101 pages • By Venture Planning Group

This new report from VPGMarketResearch.com provides an overview of the US diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for the following market segments:     -  Blood Banking     ...

3 480 4 350 2 784
Feb 2015

US Diagnostic Testing Market 2015: Segment Forecasts and Supplier Shares

101 pages • By Venture Planning Group

This new report from VPGMarketResearch.com provides an overview of the US diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for the following market segments:     -  Blood Banking     ...

3 480 4 350 2 784
Feb 2015

Cardiometabolic Drug News FEBRUARY 2015

13 pages • By Espicom Business Intelligence

Industry Trend Analysis - Afrezza's US Launch Will Test Appetite For New Insulin Delivery SystemsIndustry Brief - Merck Repatriates Diabetes/Thyroids Portfolio In RussiaIndustry Brief - Hua Raises Funds To Start Phase II TrialsIndustry Brief - FDA Approves First-In-Class Glyxambi For Adults With Type II DiabetesIndustry Brief...

825 1 114 685
Feb 2015

Latvia Medical Devices Report Q2 2015

126 pages • By Espicom Business Intelligence

The medical equipment market grew strongly until 2008, but fell sharply in 2009 and again to a lesser extent in 2012, as the country's ability to import goods fell. It was estimated at USD150.1mn in 2013, equal to USD73 per capita and 7.8% of health expenditure. A small market, it has very limited domestic production capabilities, specialising...

976 1 317 810
Feb 2015

Global Migraine Drugs Market 2015-2019

110 pages • By Infiniti Research Limited

About MigraineMigraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents...

2 400 3 000 1 920
Feb 2015

Key Pharma News 02 FEBRUARY 2015

32 pages • By Espicom Business Intelligence

Industry Trend Analysis - Approval Of Evotaz Will Keep BMS In HIV Market But Gilead Will Prevail Once AgainIndustry Trend Analysis - Several Stakeholders To Benefit From Gilead's Expanded Deals With Indian Generics CompaniesIndustry Brief - BI/Sanofi Team Up To Produce BiopharmaceuticalsIndustry Trend Analysis - Genomic Data Partnerships...

1 048 1 415 870
Feb 2015

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). A key objective of DelveInsight’s...

1 600 2 000 1 280
Feb 2015

Iron Deficiency Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Iron Deficiency Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Iron Deficiency Anemia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed...

1 600 2 000 1 280
Feb 2015

Keratoconjunctivitis sicca (Dry Eye)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Keratoconjunctivitis sicca (Dry Eye)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Keratoconjunctivitis sicca (Dry Eye). A key objective of DelveInsight’s report is to establish the understanding for...

1 600 2 000 1 280
Feb 2015

Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Lung Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline...

1 600 2 000 1 280
Feb 2015

Lichen Simplex Chronicus (Neurodermatitis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Lichen Simplex Chronicus (Neurodermatitis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Lichen Simplex Chronicus (Neurodermatitis). A key objective of DelveInsight’s report is to establish the understanding...

1 600 2 000 1 280
Feb 2015

Gouty Arthritis (Gout)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Gouty Arthritis (Gout)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Gouty Arthritis (Gout). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed...

1 600 2 000 1 280
Feb 2015

Hyperlipidemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Hyperlipidemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Hyperlipidemia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase...

1 600 2 000 1 280
Feb 2015

Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Melanoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline...

1 600 2 000 1 280
Feb 2015

Malaria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Malaria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Malaria. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs...

1 600 2 000 1 280
Feb 2015

Endocarditis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Endocarditis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Endocarditis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III...

1 600 2 000 1 280
Feb 2015

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). A key objective of DelveInsight’s...

1 600 2 000 1 280
Feb 2015

Acute Renal Failure (ARF) (Acute Kidney Injury)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Acute Renal Failure (ARF) (Acute Kidney Injury)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Acute Renal Failure (ARF) (Acute Kidney Injury). A key objective of DelveInsight’s report is to establish...

1 600 2 000 1 280
Feb 2015